cfDNA Fragment Endpoint Analysis for Genotype-Independent Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cfDNA-based clinical diagnostics rely heavily on genotypic differences between cell populations, leading to a majority of sequencing reads being uninformative and difficulty in detecting conditions where tissue damage or inflammation alters tissue-of-origin composition, such as cancer and autoimmune diseases.
Innovation Solution
Analyzing cfDNA fragment endpoints and comparing them to reference datasets to identify cell type contributors, using the genomic coordinates of enzymatic fragmentation biased by DNA-binding proteins, which differ across physiological conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genotypic differences between cell populations are used for cfDNA-based diagnostics, then diagnostic accuracy for conditions with distinct genomic profiles (e.g., fetal aneuploidy, cancer mutations) is improved, but the majority of sequencing reads become uninformative when cell populations have identical or nearly identical genomes
Solution Approach 1:
The invention shifts from analyzing genotypic parameters (nucleotide sequences, copy number variations) to analyzing fragment endpoint distribution parameters (genomic coordinates, fragmentation patterns). This parameter change enables differentiation of cell populations based on their unique fragmentation signatures rather than requiring genotypic differences, thereby maintaining diagnostic accuracy while making all sequencing reads informative.
2Adaptability or versatility
If genotypic differences are relied upon to distinguish cell populations, then conditions with distinct genetic profiles can be detected, but conditions where tissue damage or inflammation alters tissue-of-origin composition without genotypic changes (e.g., autoimmune diseases, myocardial infarction) cannot be detected
Solution Approach 1:
The fragment endpoint analysis method serves multiple diagnostic functions across diverse conditions including cancer, pregnancy, transplant monitoring, and autoimmune diseases. By analyzing fragmentation patterns rather than requiring genotype differences, the method becomes universally applicable to any condition that alters tissue-of-origin composition, making the diagnostic approach multi-functional and highly adaptable.
3Measurement precision
If deep sequencing is performed to increase coverage for copy number detection, then sensitivity for detecting genomic alterations is improved, but the cost and complexity of the test increase
Solution Approach 1:
The invention extracts and analyzes specific informative features (fragment endpoint distributions) from the sequencing data rather than requiring analysis of the entire genome at high depth. By focusing computational resources on analyzing endpoint coordinates and fragmentation patterns rather than examining all genomic positions, the method achieves comparable or superior sensitivity with lower sequencing depth, reducing both cost and complexity.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
A method for using cell-free DNA to diagnose certain conditions.